The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Flagged first, then by citations
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,008
Schneider, K., Valdez, J. L., Nguyen, J. M., Vawter, M. P., Galke, B. L., Kurtz, T. W., & Chan, J. Y. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.673756 · Cited by 83
Fibroblast activation protein (FAP) as a novel metabolic target
Sanchez-Garrido, M. A., Habegger, K. M., Clemmensen, C., Holleman, C. L., Müller, T. D., Pérez–Tilve, D., Li, P., Agrawal, A., Finan, B., Drucker, D. J., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.07.003 · Cited by 79
Liu, Y., Zhao, C., Xiao, J., Liu, L., Zhang, M., Wang, C., Wu, G., Zheng, M.-H., Xu, L.-M., Chen, Y.-P., et al. (2016) · Scientific Reports · doi:10.1038/srep31026 · Cited by 78
So, W. Y., Cheng, Q., Xu, A., Lam, K. S. L., & Leung, P. S. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.80 · Cited by 79
FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1
Kwon, M. M., O’Dwyer, S. M., Baker, R. K., Covey, S. D., & Kieffer, T. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.021 · Cited by 77
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 77
The Neuroendocrine Basis of Anorexia Nervosa and Its Impact on Bone Metabolism
Misra, M., & Klibanski, A. (2011) · Neuroendocrinology · doi:10.1159/000323771 · Cited by 81
Araki, M., Nakagawa, Y., Oishi, A., Han, S., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., IWASAKI, H. O., Sekiya, M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072148 · Cited by 82
Omar, B. A., Andersen, B., Hald, J., Raun, K., Nishimura, E., & Åhrén, B. (2013) · Diabetes · doi:10.2337/db13-0710 · Cited by 76
Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population
Reinehr, T., & Roth, C. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1110-5 · Cited by 78
Song, H., Chu, Q., Xu, D., Xu, Y., & Zheng, X. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b05177 · Cited by 81
Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins
Latko, M., Czyrek, A. A., Porębska, N., Kucińska, M. K., Otlewski, J., Zakrzewska, M., & Opaliński, Ł. (2019) · Cells · doi:10.3390/cells8050455 · Cited by 76
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 77
Xiao, Y., Liu, L., Xu, A., Zhou, P., Long, Z., Tu, Y., Chen, X., Tang, W., Huang, G., & Zhou, Z. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0229-9 · Cited by 75
Stressed Liver and Muscle Call on Adipocytes with FGF21
Luo, Y., & McKeehan, W. L. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00194 · Cited by 75
Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones
Adams, A. C., Coşkun, T., Cheng, C., O’Farrell, L. S., DuBois, S. L., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.05.005 · Cited by 75
Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia
Liu, S. Q., Tefft, B. J., Roberts, D., Zhang, L., Ren, Y., Li, Y. C., Huang, Y., Zhang, D., Phillips, H. R., & Wu, Y. H. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00362.2012 · Cited by 78
Plasma FGF21 displays a circadian rhythm during a 72‐h fast in healthy female volunteers
Andersen, B., Beck‐Nielsen, H., & Højlund, K. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04084.x · Cited by 74
Berti, L., Irmler, M., Zdichavsky, M., Meile, T., Böhm, A., Stefan, N., Fritsche, A., Beckers, J., Königsrainer, A., Häring, H.-U., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.04.002 · Cited by 73
Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome
Zhang, J., & Li, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.021 · Cited by 73
Khosravi, F., Ahmadvand, N., Bellusci, S., & Sauer, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672935 · Cited by 78
The potential function and clinical application of FGF21 in metabolic diseases
Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 73
Serum FGF-21 Levels in Type 2 Diabetic Patients
Cheng, X., Zhu, B. L., Jiang, F., & Fan, H. (2011) · Endocrine Research · doi:10.3109/07435800.2011.558550 · Cited by 73
Lifestyle precision medicine: the next generation in type 2 diabetes prevention?
Mutie, P. M., Giordano, G. N., & Franks, P. W. (2017) · BMC Medicine · doi:10.1186/s12916-017-0938-x · Cited by 75
Effects of Anorexia Nervosa on Bone Metabolism
Fazeli, P. K., & Klibanski, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00063 · Cited by 81
The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension
Huang, Z. P., Xu, A., & Cheung, B. M. Y. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0730-5 · Cited by 71
Obesity and Pancreatic Cancer: Insight into Mechanisms
Eibl, G., & Rozengurt, E. (2021) · Cancers · doi:10.3390/cancers13205067 · Cited by 76
Xu, L. L., Huang, D., Hu, Q., Wu, J., Wang, Y., & Feng, J. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515001130 · Cited by 75
Implication of hepatokines in metabolic disorders and cardiovascular diseases
Jung, T. W., Yoo, H. J., & Choi, K. M. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.03.002 · Cited by 71
Song, H., Zheng, Z., Wu, J., Lai, J., Chu, Q., & Zheng, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149670 · Cited by 73
Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice
Liu, Q., Liu, Y., Li, F., Gu, Z., Liu, M., Shao, T., Zhang, L., Zhou, G., Pan, C., He, L., et al. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108256 · Cited by 73
Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects
Lei, Y., Wang, L., Guo, K., Hou, Y., Li, N., Wang, S., Liu, X., Zhao, Q., Zhou, J., Zhao, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27584-y · Cited by 74
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Cong, W., Ling, J., Tian, H., Ling, R., Wang, Y., Huang, B., Zhao, T., Duan, Y., Jin, L., & Li, X. K. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0441 · Cited by 71
Dual actions of fibroblast growth factor 19 on lipid metabolism
Wu, X., Ge, H., Baribault, H., Gupte, J., Weiszmann, J., Lemon, B. D., Gardner, J., Fordstrom, P., Tang, J., Zhou, M., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m027094 · Cited by 71
Human FGF-21 Is a Substrate of Fibroblast Activation Protein
Coppage, A. L., Heard, K. R., DiMare, M. T., Liu, Y., Wu, W., Lai, J. H.-S., & Bachovchin, W. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151269 · Cited by 71
CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis
Park, J., Xu, X., Cho, S., Hur, K. Y., Lee, M., Kersten, S., & Lee, A. (2016) · Scientific Reports · doi:10.1038/srep27938 · Cited by 71
FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
Zhu, S., Wu, Y., Ye, X., Ma, L., Qi, J., Yu, D., Wei, Y., Lin, G., Ren, G., & Li, D. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2774-2 · Cited by 71
Fasting-induced hormonal regulation of lysosomal function
Chen, L., Wang, K., Long, A., Jia, L., Zhang, Y., Deng, H., Li, Y., Han, J., & Wang, Y. (2017) · Cell Research · doi:10.1038/cr.2017.45 · Cited by 71
Babaknejad, N., Nayeri, H., Hemmati, R., Bahrami, S., & Esmaillzadeh, A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0623-2909 · Cited by 70
Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors
Schumacher, J. D., & Guo, G. L. (2016) · BioMed Research International · doi:10.1155/2016/8323747 · Cited by 70
Spann, R. A., Morrison, C. D., & den Hartigh, L. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802541 · Cited by 76
Imamura, T. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00265 · Cited by 70
Semba, R. D., Sun, K., Egan, J. M., Crasto, C., Carlson, O. D., & Ferrucci, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2823 · Cited by 70
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70
Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis
Brahma, M. K., Adam, R. C., Pollak, N. M., Jaeger, D., Zierler, K. A., Poecher, N., Schreiber, R., Romauch, M., Moustafa, T., Eder, S., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m044784 · Cited by 70
Goto, T., Hirata, M., Aoki, Y., Iwase, M., Takahashi, H., Kim, M., Li, Y., Jheng, H., Nomura, W., Takahashi, N., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767590 · Cited by 72
Ribas, F., Villarroya, J., Hondares, E., Giralt, M., & Villarroya, F. (2014) · Biochemical Journal · doi:10.1042/bj20140403 · Cited by 69
Rader, D. J., Maratos-Flier, E., Nguyen, A., Hom, D., Ferriere, M., Li, Y., Kompa, J., Martic, M., Hinder, M., Basson, C. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab624 · Cited by 72
Nygaard, E., Møller, C. L., Kievit, P., Grove, K. L., & Andersen, B. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.79 · Cited by 69
Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology
Li, H., Zhang, J., & Jia, W. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0244-8 · Cited by 67
An, S.-Y., Lee, M. S., Yi, S., Ha, E. S., Han, S. J., Kim, H. J., Kim, D. J., & Lee, K. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.004 · Cited by 69
Kamimura, N., Ichimiya, H., Iuchi, K., & Ohta, S. (2016) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2016.8 · Cited by 69
Kruse, R., Vienberg, S. G., Vind, B. F., Andersen, B., & Højlund, K. (2017) · Diabetologia · doi:10.1007/s00125-017-4373-5 · Cited by 69
Homeostatic sensing of dietary protein restriction: a case for FGF21
Hill, C. M., Berthoud, H.-R., Münzberg, H., & Morrison, C. D. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.002 · Cited by 68
Fibroblast growth factor-21 controls dietary protein intake in male mice
Larson, K. R., Chaffin, A. T.-B., Goodson, M. L., Fang, Y., & Ryan, K. K. (2019) · Endocrinology · doi:10.1210/en.2018-01056 · Cited by 68
Kim, E., Lee, S., Lee, S.-Y., Kim, J. K., Jhun, J. Y., Na, H. S., Kim, S. Y., Choi, J. Y., Yang, C. W., Park, S., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.245 · Cited by 68
Biomarkers of mitochondrial disorders
Shayota, B. J. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00325 · Cited by 82
Tanaka, N., Takahashi, S., Fang, Z., Matsubara, T., Krausz, K. W., Qu, A., & Gonzalez, F. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.015 · Cited by 68
Cantley, J. (2014) · Mammalian Genome · doi:10.1007/s00335-014-9538-7 · Cited by 72
Clinical Significance of FGF-23 in Patients with CKD
Russo, D., & Battaglia, Y. (2011) · International Journal of Nephrology · doi:10.4061/2011/364890 · Cited by 68
Watanabe, C., Seino, Y., Miyahira, H., Yamamoto, M., Fukami, A., Ozaki, N., Takagishi, Y., Sato, J., Fukuwatari, T., Shibata, K., et al. (2011) · Diabetes · doi:10.2337/db11-0739 · Cited by 70
Harris, L.-A. L. S., Skinner, J. R., Shew, T. M., Pietka, T., Abumrad, N. A., & Wolins, N. E. (2015) · Diabetes · doi:10.2337/db14-1035 · Cited by 70
FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue
Markan, K. R., Naber, M. C., Small, S. M., Peltekian, L., Kessler, R. L., & Potthoff, M. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.03.009 · Cited by 70
Maida, A., Chan, J. S. K., Sjøberg, K. A., Zota, A., Schmoll, D., Kiens, B., Herzig, S., & Rose, A. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.009 · Cited by 68
Verzijl, C. R. C., van de Peppel, I. P., Struik, D., & Jonker, J. W. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708898 · Cited by 67
Dai, H., Hu, W., Zhang, L., Jiang, F., Mao, X., Yang, G., & Li, L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03588-w · Cited by 65
Current status and future perspectives of FGF21 analogues in clinical trials
Chui, Z. S. W., Shen, Q., & Xu, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.001 · Cited by 70
Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue
Kinoshita, K., Ozaki, N., Takagi, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2014) · Endocrinology · doi:10.1210/en.2014-1175 · Cited by 67
Weng, Y., Chabot, J., Bernardo, B. L., Yan, Q., Zhu, Y., Brenner, M. B., Vage, C., Logan, A., Calle, R. A., & Talukdar, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119104 · Cited by 67
Yang, M., Zhang, L., Wang, C., Liu, H., Boden, G. H., Yang, G., & Li, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048392 · Cited by 67
Thi, H., Tselykh, T. V., Mäkelä, J., Ho, T. H., Olkkonen, V. M., Bornhauser, B. C., Korhonen, L., Zelcer, N., & Lindholm, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.341248 · Cited by 67
The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
Ramos, D. C., Almeda‐Valdés, P., Aguilar-Salinas, C. A., Cuevas-Ramos, G., Cuevas-Sosa, A., & Gomez-Perez, F. J. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804396 · Cited by 70
Potential roles of fibroblast growth factor 21 in the brain
Sa‐nguanmoo, P., Chattipakorn, N., & Chattipakorn, S. C. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-015-9789-3 · Cited by 70
Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
Cheng, P., Zhang, F., Yu, L., Lin, X., He, L., Li, X., Lu, X., Yan, X., Tan, Y., & Zhang, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1540267 · Cited by 66
The FGF21 Receptor Signaling Complex
Kilkenny, D. M., & Rocheleau, J. V. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.02.008 · Cited by 68
Pan, Y., Wang, B., Zheng, J., Xiong, R., Fan, Z., Ye, Y., Zhang, S., Li, Q., Gong, F., Wu, C., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14007 · Cited by 67
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 70
Hepatic CREB3L3 Controls Whole-Body Energy Homeostasis and Improves Obesity and Diabetes
Nakagawa, Y., Satoh, A., Yabe, S., Furusawa, M., Tokushige, N., Tezuka, H., Mikami, M., Iwata, W., Shingyouchi, A., Matsuzaka, T., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1113 · Cited by 66
van Malenstein, H., Gevaert, O., Libbrecht, L. J., Daemen, A., Allemeersch, J., Nevens, F., Cutsem, E. V., Cassiman, D. M., Moor, B. D., Verslype, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3274 · Cited by 65
Stemmer, K., Bielohuby, M., Grayson, B. E., Begg, D. P., Chambers, A. P., Neff, C., Woods, S. C., Erben, R. G., Tschöp, M. H., Bidlingmaier, M., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2130 · Cited by 66
Crooks, D. R., Natarajan, T. G., Jeong, S. Y., Chen, C., Park, S. Y., Huang, H., Ghosh, M. C., Tong, W.-H., Haller, R. G., Wu, C. H., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt393 · Cited by 65
Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
Kohara, M., Masuda, T., Shiizaki, K., Akimoto, T., Watanabe, Y., Honma, S., Sekiguchi, C., Miyazawa, Y., Kusano, E., Kanda, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178971 · Cited by 66
Andersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66
Song, L., Wang, L., Hou, Y., Zhou, J., Chuchu, C., Ye, X., Dong, W., Gao, H. F., Liu, Y., Qiao, G., et al. (2022) · Hepatology · doi:10.1002/hep.32404 · Cited by 66
Ables, G. P., Ouattara, A., Hampton, T., Cooke, D., Perodin, F., Augie, I., & Orentreich, D. S. (2015) · Scientific Reports · doi:10.1038/srep08886 · Cited by 67
The Klotho gene family and the endocrine fibroblast growth factors
Kurosu, H., & Kuro‐o, M. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282ffd994 · Cited by 65
Han, S. H., Choi, S. H., Cho, B. J., Lee, Y., Lim, S. K., Park, Y. J., Moon, M. K., Lee, H. K., Kang, S., Han, D. S., et al. (2010) · Metabolism · doi:10.1016/j.metabol.2010.03.018 · Cited by 65
Lips, M. A., de Groot, G. H., Berends, F. J., Wiezer, M. J., van Wagensveld, B. A., Swank, D. J., Luijten, A. A. P. M., van Dijk, K. W., Pijl, H., Jansen, P. L. M., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12496 · Cited by 65
Kralisch, S., Tönjes, A., Krause, K., Richter, J., Lössner, U., Kovacs, P. L., Ebert, T., Blüher, M., Stümvoll, M., & Faßhauer, M. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0367 · Cited by 64
Increased FGF21 plasma levels in humans with sepsis and SIRS
Gariani, K., Drifte, G., Dunn-Siegrist, I., Pugin, J., & Jornayvaz, F. R. (2013) · Endocrine Connections · doi:10.1530/ec-13-0040 · Cited by 65
Xu, L., Huang, D., Hu, Q., Wu, J., Wang, Y., & Feng, J. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114515002901 · Cited by 65
Ahmad, B., Vohra, M. S., Saleemi, M. A., Serpell, C. J., Fong, I. L., & Wong, E. H. (2021) · Biochimie · doi:10.1016/j.biochi.2021.01.015 · Cited by 68
Peripheral signalling involved in energy homeostasis control
Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 66
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 66
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
Aaldijk, A. S., Verzijl, C. R. C., Jonker, J. W., & Struik, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150222 · Cited by 63
Sun, Q., Li, L., Li, R., Yang, M., Liu, H., Nowicki, M. J., Zong, H., Xu, J., & Yang, G. (2009) · Annals of Medicine · doi:10.1080/07853890902729760 · Cited by 64
Metformin Stimulates FGF21 Expression in Primary Hepatocytes
Nygaard, E. B., Vienberg, S. G., Ørskov, C., Hansen, H. S., & Andersen, B. (2012) · Experimental Diabetes Research · doi:10.1155/2012/465282 · Cited by 62
Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system
Lee, H. U., McPherson, Z. E., Tan, B., Korecka, A., & Pettersson, S. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1486-0 · Cited by 65
Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues
Lin, X., Liu, Y. B., & Hu, H. (2017) · Biomedical Reports · doi:10.3892/br.2017.890 · Cited by 61
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
